CN104082742B - A kind of functional food nursing one's health blood glucose balance - Google Patents
A kind of functional food nursing one's health blood glucose balance Download PDFInfo
- Publication number
- CN104082742B CN104082742B CN201410320488.6A CN201410320488A CN104082742B CN 104082742 B CN104082742 B CN 104082742B CN 201410320488 A CN201410320488 A CN 201410320488A CN 104082742 B CN104082742 B CN 104082742B
- Authority
- CN
- China
- Prior art keywords
- blood glucose
- functional food
- parts
- raw material
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 84
- 210000004369 blood Anatomy 0.000 title claims abstract description 83
- 239000008280 blood Substances 0.000 title claims abstract description 83
- 239000008103 glucose Substances 0.000 title claims abstract description 83
- 235000013376 functional food Nutrition 0.000 title claims abstract description 59
- 230000036541 health Effects 0.000 title claims abstract description 16
- 230000000474 nursing effect Effects 0.000 title claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 46
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 38
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 34
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 19
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 19
- 239000011718 vitamin C Substances 0.000 claims abstract description 19
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 17
- 229940046009 vitamin E Drugs 0.000 claims abstract description 17
- 239000011709 vitamin E Substances 0.000 claims abstract description 17
- 230000003750 conditioning effect Effects 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 33
- 235000013305 food Nutrition 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000003914 insulin secretion Effects 0.000 abstract description 7
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 23
- 206010012601 diabetes mellitus Diseases 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 235000000346 sugar Nutrition 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000007689 inspection Methods 0.000 description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013118 diabetic mouse model Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- YMCZETULMSWVBI-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.OC(=O)COC1=CC=C(Cl)C=C1 YMCZETULMSWVBI-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011697 diabetes animal model Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of functional food nursing one's health blood glucose balance, this food is made up of the raw material of following parts by weight: Folium Mori extract 30-50 part, Cortex Cinnamomi extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part.In the present invention, above-mentioned several raw material is except respective effect, it blends into one after this food of formation, tests prove that also have and can well regulate islet function, help internal insulin secretion to reach balance, regulate carbohydrate metabolism, also can reduce blood fat, it is prevented that blood vessel scleratheroma, it is possible to well adjust the function reaching conditioning blood glucose balance and complication prevention simultaneously.
Description
Technical field
The present invention relates to field of functional food, particularly a kind of functional food nursing one's health blood glucose balance.
Background technology
Diabetes are a kind of common diseases, are come the 3rd after tumor, cardiovascular and cerebrovascular disease, one of chronic disease of serious harm human health.Its impact includes the long-term damage of each organ, dysfunction and exhaustion.Frequently, whether so not serious diabetic symptom is；But, long-term hyperglycemia causes cardiovascular diseases, retinopathy (blindness, blind), nephropathy (renal failure) and ulcer of foot, amputation etc..The rapid decrease of cognitive function and other brain functions or tissue injury are often by diabetes-induced or concurrent.
Diabetes be a kind of cause because of body hypoinsulinism or insulin resistant etc. a series of saccharides, lipid, protein metabolism disorder syndrome.In recent years, the prevalence of China's diabetes increases sharply.The prevalence of whole nation generaI investigation diabetes in 1980 is 0.67%, and within 1994, diabetes prevalence rises to 2.51%.2007-2008, China has carried out the extensive Epidemiological study of diabetes.Result of study shows, the prevalence of whole nation diabetes has reached 9.7%, and the prevalence of prediabetes is up to 15.5%.It means that China has become the country that whole world diabetics is maximum.
At present, primary treatments to type ii diabetes is manual injection's insulin or orally-taken blood sugar reducing medicine both at home and abroad.Some medicines have significant hypoglycemic activity, but long-term taking also there will be adverse side effect (such as glucinan or α glucosidase inhibitor).The blood-sugar decreasing active having no side effect is one of importance of functional food research and development.Type ii diabetes slower development, at early period of origination, due to compensatory insulin secretion, blood glucose maintains and normal physiologic values, hinders or postpone the diagnosis of the state of an illness.Meanwhile, the chronic overstimulation of β cell can be caused it to exhaust and degenerates, cause that its insulin secreting ability is gradually lowered.The temporary transient dormancy of inducing beta cell can improve its insulin secreting ability, thus delaying the development of type ii diabetes.But, have apparent side effect at clinical practice insulin secretion inhibitor.The wholefood that exploitation regulates insulin secretion is extremely important.The famous endocrine expert's money of China is honourably obtained and is pointed out, High-risk Group of Diabetes should change ill such a simple clinical concept of taking medicine, because diabetes are not depend merely on to take medicine to treat the disease that just can solve problem.Therefore, finding and can be used for treating diabetes, the natural bioactivity substance of conditioning blood glucose balance or functional food are one of important hot issues of the outer treating diabetes research of Present Domestic.
Functional food refers to the food with trophic function, sensory function and adjustment physiological activity function, including: strengthen the food of human body constitution (strengthening immunocompetence, activate lymphsystem etc.)；Prevent the food of disease (hypertension, diabetes, coronary heart disease, constipation and tumor etc.)；Get well the food of (control cholesterol, prevent platelet aggregation, regulate hemopoietic function etc.)；Regulate the food of body rhythms (nerve centre, nerve ending, picked-up and absorption function etc.) and the food of slow down aging.The research and development of functional food still belong to new branch of science and field in China, are the products of continuous mixing together multidisciplinary, multi-field, relate to threpsology, pharmacy, physiology, preventive medicine, biological engineering, Food Science.Therefore, develop the functional food safely and effectively nursing one's health blood glucose balance diabetes patient is significant.
Summary of the invention
Present invention seek to address that one of technical problem in prior art problem, for this, the invention provides a kind of functional food nursing one's health blood glucose balance, include the islets of langerhans adjustment factor, adjustment islet function can be played, internal insulin secretion is helped to reach balance, thus reaching to regulate carbohydrate metabolism, the function of conditioning blood glucose balance.
In one aspect of the invention, the invention provides a kind of compositions, be mainly made up of the raw material of following parts by weight: Folium Mori extract 30-50 part, Cortex Cinnamomi extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part.
It addition, compositions according to the above embodiment of the present invention can also have following additional technical characteristic:
In an embodiment of the present invention, the compositions of the present invention farther includes the mixed raw material one-tenth of following parts by weight: Folium Mori extract 45 parts, Cortex Cinnamomi extract 40 parts, vitamin C 10 parts, vitamin E 5 parts.
In an embodiment of the present invention, the compositions of the present invention farther includes the mixed raw material one-tenth of following parts by weight: Folium Mori extract 45 parts, Cortex Cinnamomi extract 45 parts, vitamin C 5 parts, vitamin E 5 parts.
In an embodiment of the present invention, the compositions of the present invention farther includes the mixed raw material one-tenth of following parts by weight: Folium Mori extract 50 parts, Cortex Cinnamomi extract 40 parts, vitamin C 5 parts, vitamin E 5 parts.
In embodiments of the invention, the preparation method additionally providing a kind of functional food, according to embodiments of the invention, its preparation method is as follows:
A. by Folium Mori extract 30-50 part, Cortex Cinnamomi extract 30-50 part, vitamin C 5-10 part, the powder raw material of vitamin E 5-10 part puts in blender respectively, stirs；
B. the powder raw material stirred is put into microwave dryer, dries and sterilizing；
C. the powder raw material after drying sterilizing is pulverized, sieve, obtain fine powder；
D. described fine powder material forming is made functional food；
According to some embodiments of the present invention, in above-mentioned preparation method, the moisture of described powder raw material is 10%-20%.
According to some embodiments of the present invention, in above-mentioned preparation method, it is 2-2.5cm that described powder raw material puts into the thickness of microwave dryer.
According to some embodiments of the present invention, in above-mentioned preparation method, described powder raw material is dried and sterilising temp is 60-80 DEG C, and the time is 4-10 minute.
According to some embodiments of the present invention, in above-mentioned preparation method, after the drying of described powder raw material, moisture is less than 7%.
According to some embodiments of the present invention, in above-mentioned preparation method, described by dry and sterilizing after powder raw material pulverize, cross 100 mesh sieves.
According to some embodiments of the present invention, the functional food in the present invention is at least one form of capsule, tablet or electuary.
According to embodiments of the invention, the pharmaceutical composition of the present invention may be used for the blood glucose balance of conditioning diabetes patient.
Some concrete examples according to the present invention, the present invention establishes a kind of tissue of experimental diabetic mice model, the functional food of the conditioning blood glucose balance of the present invention has been carried out functional experiment, find that normal mouse and two kinds of diabetes models are all had significant blood sugar reducing function by a kind of functional food nursing one's health blood glucose balance provided by the invention, meanwhile, a kind of functional food nursing one's health blood glucose balance provided by the invention has also been carried out Oral toxicity test by the present invention, the safety evaluatio experiment of binomial mutagenicity test (PCEMNR number micronucleus test and sperm malformation test) and 30 days feeding trials, test shows, by acute toxicity grading criteria evaluation, this given the test agent belongs to nontoxic level.
In the present invention, above-mentioned several raw material is except respective effect, it blends into one after this food of formation, tests prove that also have and can well regulate islet function, help internal insulin secretion to reach balance, regulate carbohydrate metabolism, also can reduce blood fat, it is prevented that blood vessel scleratheroma, it is possible to well adjust the function reaching conditioning blood glucose balance and complication prevention simultaneously.Therefore, this food has the function well nursing one's health blood glucose balance, user can be made to regulate blood glucose, reduce using and relying on antidiabetic drug, reduce the toxic and side effects that medicine brings to health.On safe regulating and controlling blood sugar, this food is that current safety effectively can nurse one's health the health food of blood glucose balance by regulating insulin secretion in islet function, dummy and reach balance, reduce blood fat etc..
Just complete it should be noted that the medical composition and its use of the present invention is present inventor through arduous creative work and Optimization Work.
The additional aspect of the present invention and advantage will part provide in the following description, and part will become apparent from the description below, or is recognized by the practice of the present invention.
Detailed description of the invention
Embodiments of the invention are described below in detail.The embodiments described below is illustrative of, and is only used for explaining the present invention, and is not considered as limiting the invention,
A kind of functional food nursing one's health blood glucose balance provided by the invention, the mixed raw material including following parts by weight becomes:
Folium Mori extract 30-50 part, Cortex Cinnamomi extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part, these four kinds of raw materials are all bought from Jia Kang source, Beijing Chemical Co., Ltd..
Embodiment 1:
Thering is provided a kind of compositions, the mixed raw material including following parts by weight becomes: Folium Mori extract 45 parts, Cortex Cinnamomi extract 40 parts, vitamin C 10 parts, 5 parts of powder raw materials of vitamin E.
Embodiment 2:
Thering is provided a kind of compositions, the mixed raw material including following parts by weight becomes: Folium Mori extract 45 parts, Cortex Cinnamomi extract 45 parts, vitamin C 5 parts, 5 parts of powder raw materials of vitamin E.
Embodiment 3:
Thering is provided a kind of compositions, the mixed raw material including following parts by weight becomes: Folium Mori extract 50 parts, Cortex Cinnamomi extract 40 parts, vitamin C 5 parts, 5 parts of powder raw materials of vitamin E.
Embodiment 4:
Thering is provided a kind of compositions, the mixed raw material including following parts by weight becomes: Folium Mori extract 30 parts, Cortex Cinnamomi extract 50 parts, vitamin C 10 parts, 0 part of powder raw material of vitamin e1.
Preparation method: the invention provides the preparation method of a kind of food and include stirring, dry and sterilizing, pulverizing and forming step, specific as follows:
Embodiment 5:
First by conformance with standard (quality standard in Q/WHF0003S-2012, as follows) Folium Mori extract 45 parts, Cortex Cinnamomi extract 40 parts, vitamin C 10 parts, 5 parts of powder raw materials (parts by weight) of vitamin E put in blender, so as to stir, and to control raw material water content be 10～20%；Being placed in microwave dryer by the raw material mixed by the thickness uniform spreading of 2～2.5cm again, carry out sterilizing and drying under temperature 60～80 DEG C, 4～10 minutes time condition, after drying, moisture is less than 7%；Then, will dry and powder raw material after sterilizing is pulverized, sieve, 100 orders, 80 orders or 60 mesh sieves when sieving, can be used, wherein preferred 100 mesh sieve, obtain fine powder；Finally, require to make fine powder raw material capsule or tablet or electuary or other kind of packaging product according to functions of the state food technology.
Embodiment 6: first by standard compliant powder raw material (parts by weight) Folium Mori extract 45 parts, Cortex Cinnamomi extract 45 parts, vitamin C 5 parts, in 5 parts of input blenders of vitamin E, so as to stir, and to control raw material water content be 10～20%；Following operation is with embodiment 5.
Embodiment 7: first by standard compliant powder raw material (parts by weight) Folium Mori extract 50 parts, Cortex Cinnamomi extract 40 parts, vitamin C 5 parts, in 5 parts of input blenders of vitamin E, so as to stir, and to control raw material water content be 10～20%；Following operation is with embodiment 5.
Embodiment 8: first by standard compliant powder raw material (parts by weight) Folium Mori extract 30 parts, Cortex Cinnamomi extract 50 parts, vitamin C 10 parts, in 0 part of input blender of vitamin e1, so as to stir, and to control raw material water content be 10～20%；Following operation is with embodiment 5.
Functional experiment is tested:
The compositions of the present invention, by setting up tissue of experimental diabetic mice model, has been carried out functional experiment test by the present inventor
Embodiment 9: the experiment test of effect of a kind of functional food provided by the invention
1. materials and methods
1.1 materials
Sample: the one provided any one of the above embodiment of the present invention 1 to 4 regulates blood glucose balance functional food, is provided by Kai Ze (Wuhan) health control company limited, and human body recommended amounts is 30mg/ (d kg).
Laboratory animal:
1. Kunming mouse, male, body weight 18～22g, Hubei Province's Experimental Animal Center provide, freely ingest, drink water.Animal feeding indoor arrange 12h day-night cycle device, and room temperature maintains (22 ± 2) DEG C.Feeds utilized for standard mouse food, energy density is 15.2kJ/g (energy percentage is protein 23 .1% respectively, fat 16.5%, carbohydrate 60.4%).
2.KKAy mice, i.e. heritability diabetes animal model, show as type ii diabetes feature, male, body weight (30 ± 2) g, blood glucose screening criteria is 4h blood glucose on an empty stomach > 8.0mmol/L, thered is provided by Chinese Academy of Medical Sciences animal, ibid, feedstuff is special high lipid food to feeding environment, and follower provides in the lump.
Experimental drug: alloxan, trade name: Alloxan, derive from Sigma company, lot number: 51kl132.
1.2 experimental techniques
Tissue of experimental diabetic mice model is set up: take normal kunming mice, with PH=4-5, concentration is 0.5mol/L citric acid solution preparation alloxan solution, by 200mg/kgbw lumbar injection, destroy mice pancreatic B cell, after injecting 4 hours, give 10% glucose solution gavage, to avoid animal to cause convulsions death due to lasting hypoglycemia, after observing 72 hours, measure the mice on an empty stomach blood glucose of 4 hours, blood glucose > animal of 10mmol/L is used for testing.Animal pattern possesses type i diabetes feature.
1.3 experimental procedures
A kind of functional food experimental technique on the impact of normal Mouse oral glucose tolerance (OGTT) provided by the invention: take normal mouse 24, stochastic averagina is divided into experimental group and matched group, 12 hours on an empty stomach, disposable through injection 1:3 give glucose 3g/kgbw, give a kind of functional food 1g/kgbw regulating blood glucose balance according to preliminary result experimental group is simultaneously disposable through injection 1:3, measure 0.5h, 1h, 2h blood glucose after being administered.
A kind of functional food provided by the invention is on the experimental technique of the impact of I, type ii diabetes mouse blood sugar under random meal situation: each 20 of 2 kinds of diabetic mices, it is divided equally into experimental group and matched group all at random, experimental group is disposable gives a kind of functional food 1g/kgbw regulating blood glucose balance through injection 1:3, remove feedstuff simultaneously, measure 2h, 4h blood glucose after being administered.
A kind of functional food provided by the invention experimental technique on I, the impact of type ii diabetes mice fasting glucose: each 20 of 2 kinds of diabetic mices, it is divided equally into experimental group and matched group all at random, animal fasting 4h before experiment, the disposable per os of experimental group gives CPS1g/kgbw, measures 2h, 4h blood glucose after being administered respectively.Each experiment contrast group all gives isopyknic normal saline above, and all the other operations are identical with experimental group.
1.4 observation index blood sugar detections take animal tail vein glucose oxidase method, and instrument is Johnson & Johnson of U.S. Sure Step blood glucose monitoring system and special test paper.
Statistical disposition t inspection is compared between organizing, and represents with ± s.
2 functional experiment results
The result that affects of normal Mouse oral glucose tolerance (OGTT) is shown by 2.1 a kind of functional foods regulating blood glucose balance provided by the invention, a kind of functional food regulating blood glucose balance provided by the invention can significantly improve normal mouse glucose tolerance, in table 1, experimental data demonstrates experimental group and is significantly smaller than matched group, matched group is 0.5h after glucose gavage, 1h blood glucose raises 167% and 78% respectively, and experimental group only raises 120% and 46%, two groups are compared difference and have significant (P < 0.05), after administration 2h, two treated animal blood glucose reach fairly horizontal.
The table 1 impact on normal glucose tolerance in mice
mmol/l
Note: with matched group than P < 0.05, P < 0.01
Under 2.2 random meal situation, the impact on various blood glucose in diabetic mice of a kind of functional food regulating blood glucose balance
In table 2, the data of test demonstrate a kind of functional food provided by the invention impact on random type i diabetes mouse blood sugar of taking food, random feed type i diabetes mouse blood sugar is had the effect of significantly reducing by a kind of functional food regulating blood glucose balance, and goes back highly significant after its hypoglycemic activity 4h upon administration.Matched group 2h, 4h blood glucose upon administration declines 3% and 19% respectively, and experimental group declines 21% and 42% respectively.
The table 2 effect to random type 1 diabetes mouse blood sugar of taking food
mmol/L
Note: with matched group than P < 0.05, P < 0.01
Table 3 demonstrates a kind of functional food provided by the invention impact on random type 2 diabetes mellitus mouse blood sugar of taking food, matched group 2h, 4h blood glucose upon administration declines 4% and 14% respectively, experimental group blood glucose declines 25% and 38% respectively, and two groups are compared difference and have significant.
The table 3 effect to random type 2 diabetes mellitus mouse blood sugar of taking food
mmol/L
Note: with matched group than P < 0.05
The effect to various diabetic mice fasting glucose of the 2.3 a kind of functional foods provided by the invention
In table 4, data result shows, matched group 2h, 4h blood glucose upon administration declines 11% and 31% respectively, and experimental group blood glucose declines 46% and 62% respectively.After gavage, type i diabetes mice fasting glucose had the effect of significantly reducing.
The table 4 impact on type 1 diabetes mice fasting glucose
mmol/L
Note: with matched group than P < 0.05, P < 0.01
Table 5 shows a kind of functional food provided by the invention effect to type ii diabetes mice fasting glucose, can significantly reduce type ii diabetes mice fasting glucose after gavage.Matched group 2h, 4h blood glucose upon administration declines 7% and 19% respectively, and experimental group blood glucose declines 24% and 38% respectively, and two groups of falls compare difference and have significant.
The table 5 impact on type 2 diabetes mellitus mice fasting glucose
mmol/L
Note: with matched group than P < O.05
In conjunction with above each experimental data, inventor draws to draw a conclusion, the carbohydrate tolerance of normal mouse be test result indicate that by the present invention, disposable give after a kind of functional food 1g/kgbw provided by the invention through 1:3, experimental group blood sugar level is substantially lower than matched group at 0.5h, 1h, points out a kind of functional food provided by the invention to have the effect reducing Postprandial peak glucose.When giving type i diabetes and type ii diabetes mice one provided by the invention functional food 1g/kgbw dosage, no matter it is fasting glucose or random blood sugar, there is significant decline, show that this food can reduce fasting glucose and the random blood sugar of 2 kinds of diabetic mices.There is multiple sugar-lowering components in a kind of functional food provided by the invention, except glycoside, also have alkaloid insulinoid polypeptide compound similar to one, mainly have para-insulin effect, stimulate B cell excreting insulin and protection pancreas effect.
Safety assessment is tested
Present invention also offers a kind of assessment experiment, pass through acute toxicity test in mice, PCEMNR number micronucleus test, the security performance of a kind of functional food provided by the invention has been evaluated by mouse inbred strain, 30 days feeding trials and the test of hematological examination result and animal pathologic diagnosis.
Embodiment 10:
Acute toxicity test in mice
Test method:
SPF level Kunming mouse acute oral toxicity test to two kinds of sexes, the toxicology method of inspection of method reference " health food inspection and assessment technique specification " 2003 editions, respectively 15 female mices and 15 male mices are carried out twice gavage, each dosage is 20g/kgBW (being equivalent to 667 times of crowd recommended intake 0.03g/kgBW), through the observation period of 14 days, result of the test was in Table 6.
6 one kinds of table regulates the functional food of blood glucose balance to acute toxicity test in mice result
Experimental data shows that two treated animals all do not observe Novel presentation, has no animal poisoning symptom and dead generation in two weeks.By acute toxicity grading criteria evaluation, this given the test agent belongs to nontoxic level.
Embodiment 11:
PCEMNR number micronucleus test
SPF level Kunming mouse Polychromatic erythrocyte number micronucleus test to two kinds of sexes, method is by the toxicology method of inspection of " health food inspection with assessment technique specification " 2003 editions, and result is in Table 7.
7 one kinds of table regulates the functional food of blood glucose balance to PCEMNR number micronucleus test result
Note: compare * * P < 0.01 with negative control group
Experimental data shows, compare with negative control group, positive controls male and female micronuclei in mice rate there were significant differences property (P < 0.01), and given the test agent each dosage group male and female micronuclei in mice rate compares with negative control group, difference that there are no significant (P > 0.05), and all within normal range, it was shown that this given the test agent bone marrow micronucleus test result is negative.
Embodiment 12:
Mouse inbred strain
To SPF level Kunming mouse sperm malformation test, method is by the toxicology method of inspection of " health food inspection and assessment technique specification " 2003 editions, and result is in Table 8.
8 one kinds of table regulates the functional food of blood glucose balance to mouse inbred strain result
Note: compare * * P < 0.01 with negative control group
Experimental data shows, compare with negative control group A, positive controls mouse sperm deformity rate has significant difference (P < 0.01), and given the test agent each dosage group mouse sperm deformity rate compares with negative control group, difference that there are no significant (P > 0.05), it was shown that this given the test agent sperm malformation test result is negative.
Embodiment 13:
30 days feeding trials
30 days feeding trials of SPF level Wistar rat to two kinds of sexes, method is by the toxicology method of inspection of " health food inspection with assessment technique specification " 2003 editions, and result is as follows: in process of the test, animal is without death, and hair is normal, behavior expression without exception.
On rat body weight, food-intake, food utilization impact, result is in Table 9-11.
9 one kinds of table regulates the functional food impact (mean ± standard deviation) on rat body weight of blood glucose balance
10 1 kinds of table regulates the functional food impact (mean ± standard deviation) on rats eating amount of blood glucose balance
11 1 kinds of table regulates the functional food impact (mean ± standard deviation) on rat chow utilization rate of blood glucose balance
From table 9-11, there are no significant (P > 0.05) to rat body weight, food-intake, food utilization and negative control group comparing difference for each dosage group of given the test agent.
Embodiment 14:
Hematological examination result is tested
Rat serum routine examination affected result, rat leukocyte classification affected result, rat blood biochemical analysis affected result respectively in Table 12, table 13 and table 14.
12 1 kinds of table regulates the functional food impact (mean ± standard deviation) on rat serum routine examination result of blood glucose balance
13 1 kinds of table regulates the impact (mean ± standard deviation) that rat leukocyte is classified by the functional food of blood glucose balance
14 1 kinds of table regulates the functional food impact (mean ± standard deviation) on rat blood biochemical analysis of blood glucose balance
Continued
In table 12, data show, each dosage group of given the test agent compares with negative control group, difference that there are no significant (P > 0.05), and all in range of normal value.In table 13, data show, each dosage group of given the test agent compares with negative control group, difference that there are no significant (P > 0.05), and all in range of normal value.In table 14, data show, given the test agent each dosage group rat blood serum alanine aminotransferase (ALT), glutamate pyruvate transaminase (AST), blood urea nitrogen (BUN), CRE, glucose (GLU), TRI, CHO, ALB, TP measurement result compare with negative control group, difference that there are no significant (P > 0.05), and all in range of normal value.
In conjunction with above each experimental data, inventor draws to draw a conclusion, and a kind of functional food regulating blood glucose provided by the invention is the food of a kind of safety non-toxic, can play the effect regulating blood glucose balance, be again safety non-toxic to diabetes patient.
Although an embodiment of the present invention has been shown and described, it will be understood by those skilled in the art that, these embodiments can being carried out multiple change, amendment, replacement and modification when without departing from principles of the invention and objective, the scope of the present invention is limited by claim and equivalent thereof.
Claims (9)
1. the functional food nursing one's health blood glucose balance, it is characterised in that become by the mixed raw material of following parts by weight: Folium Mori extract 30-50 part, Cortex Cinnamomi extract 30-50 part, vitamin C 5-10 part, vitamin E 5-10 part.
2. the functional food of conditioning blood glucose balance according to claim 1, it is characterised in that described functional food is at least one form of capsule, tablet or electuary.
3. the functional food of conditioning blood glucose balance according to claim 1, it is characterised in that become by the mixed raw material of following parts by weight:
Folium Mori extract is 45 parts, and Cortex Cinnamomi extract is 40 parts, and vitamin C is 10 parts, and vitamin E is 5 parts.
4. the functional food of conditioning blood glucose balance according to claim 1, it is characterised in that become by the mixed raw material of following parts by weight:
Folium Mori extract is 45 parts, and Cortex Cinnamomi extract is 45 parts, and vitamin C is 5 parts, and vitamin E is 5 parts.
5. the preparation method of the functional food nursing one's health blood glucose balance, it is characterised in that prepare through the following steps:
A. by Folium Mori extract 30-50 part, Cortex Cinnamomi extract 30-50 part, vitamin C 5-10 part, the powder raw material of vitamin E 5-10 part puts in blender respectively, stirs；
B. the powder raw material stirred is put into microwave dryer, dries and sterilizing；
C. the powder raw material after drying sterilizing is pulverized, sieve, obtain fine powder；
D. functional food is made in described fine powder molding.
6. the preparation method of the functional food of conditioning blood glucose balance according to claim 5, it is characterised in that it is 2-2.5cm that described powder raw material puts into the thickness of microwave dryer.
7. the preparation method of the functional food of conditioning blood glucose balance according to claim 5, it is characterised in that described powder raw material is dried and sterilising temp is 60-80 DEG C, and the time is 4-10 minute.
8. the preparation method of the functional food of conditioning blood glucose balance according to claim 5, it is characterised in that after the drying of powder raw material described in described b step, moisture is less than 7%.
9. the preparation method of the functional food of conditioning blood glucose balance according to claim 5, it is characterised in that described by dry and sterilizing after powder raw material pulverize, cross 100 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410320488.6A CN104082742B (en) | 2014-07-04 | 2014-07-04 | A kind of functional food nursing one's health blood glucose balance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410320488.6A CN104082742B (en) | 2014-07-04 | 2014-07-04 | A kind of functional food nursing one's health blood glucose balance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104082742A CN104082742A (en) | 2014-10-08 |
| CN104082742B true CN104082742B (en) | 2016-06-29 |
Family
ID=51630590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410320488.6A Active CN104082742B (en) | 2014-07-04 | 2014-07-04 | A kind of functional food nursing one's health blood glucose balance |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104082742B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106723021A (en) * | 2016-11-28 | 2017-05-31 | 武汉哈福科技有限公司 | A kind of functional food for improving the health care of sleep |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11187843A (en) * | 1997-12-25 | 1999-07-13 | Lotte Co Ltd | Food and beverage composition for improving obesity and food and beverage containing the same |
| CN100356869C (en) * | 2005-12-27 | 2007-12-26 | 武汉哈福科技有限公司 | Health-care food with functions of anti-senium and cosmetic |
| CN102273621B (en) * | 2010-06-09 | 2015-07-29 | 苏州润新生物科技有限公司 | A kind of food of prevention and therapy diabetes or health food |
| CN102727586B (en) * | 2011-04-02 | 2015-03-11 | 苏州润新生物科技有限公司 | Composition for preventing and treating diabetes |
| CN102727706A (en) * | 2011-04-02 | 2012-10-17 | 苏州润新生物科技有限公司 | Composition for preventing and treating diabetes |
| CN102511712A (en) * | 2011-12-19 | 2012-06-27 | 苏州先阔生物科技有限公司 | Xylo-oligosaccharide-containing healthcare food auxiliary for blood sugar reduction |
-
2014
- 2014-07-04 CN CN201410320488.6A patent/CN104082742B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104082742A (en) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102406860B (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN106360310A (en) | Composition for dropping after meal blood sugar and application thereof | |
| CN101878906B (en) | Health care food with auxiliary hyperglycemic function and preparation method thereof | |
| CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
| CN102614499B (en) | Yak skin collagen compound traditional Tibetan medicine with anti-fatigue effect and preparation process thereof | |
| CN105079089A (en) | Preparation method of kudzuvine root and bitter gourd health-care food assisting in reducing blood glucose | |
| CN105596646A (en) | Medicine, health-care product or food composition for controlling blood glucose and treating abnormal blood lipid metabolism | |
| CN104857088A (en) | Preparation method of mulberry leaf compound capsule for lowering blood glucose in assistant manner | |
| CN106723021A (en) | A kind of functional food for improving the health care of sleep | |
| CN100444746C (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN102847159A (en) | A glucose metabolism enhancer | |
| CN103736071B (en) | A kind of composition with auxiliary hyperglycemic effect and application thereof, preparation method | |
| CN105725187A (en) | Blood sugar reducing composition and application in preparation of foods and health-care foods | |
| CN101356975A (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN104082742B (en) | A kind of functional food nursing one's health blood glucose balance | |
| CN1706281A (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| CN101147584B (en) | Health-care food capable of preventing and treating diabetes and preparation method thereof | |
| CN100531783C (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| CN104127816B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| WO2018072276A1 (en) | Health-care food and preparation method therefor | |
| CN107669763A (en) | A kind of compound blood fat reducing health products of sea grass polysaccharide and preparation method thereof | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN104173734B (en) | A kind of pharmaceutical composition for treating IGR and preparation method thereof | |
| CN1286503C (en) | Combination of Chinese traditional medicine possessing function of regulating blood sugar, blood fat, preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170105 Address after: 430000 Hubei Province, Wuhan East Lake Development Zone high-tech road No. 666 Wuhan national biological industry base project B, C, D & B1 building area Patentee after: Wuhan Hava Bioscience Co., Ltd. Address before: 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 Wuhan city industrial base project B, C, D, B1 block Patentee before: Keyser (Wuhan) Health Management Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 430075, Hubei, East Lake Province Development Zone, 666 high-tech Avenue, Wuhan city industrial base project B, C and D District B1 building, Wuhan Patentee after: HAFU TECHNOLOGY (WUHAN) GROUP Co.,Ltd. Address before: 430000, Hubei, East Lake Development Zone, 666 hi tech Avenue, Wuhan National Bio industrial base project B, C and D District R & D building B1 building, Wuhan Patentee before: WUHAN HAVA BIOSCIENCE Co.,Ltd. |
|
| CP03 | Change of name, title or address |